

Page Memorial Hospital

Monoclonal Antibodies for COVID 19

EMAIL orders to Infusion Center at: PMHinfusion@valleyhealthlink.com

ALLERGIES					
Weight in Kilograms Height					
DIAGNOS	SIS: COVID-19 STATUS: OUTPATIENT HCPCS Codes: Q0222 (drug), M0222 (admin)				
	Emergency Use Authorization				
Fc	or non-hospitalized patients, not on oxygen or without an increase in home oxygen flow rate				
	FORM MUST BE COMPLETED IN ENTIRETY OR ORDER WILL BE REJECTED				
	TIVE SARS-CoV-2 test: YES INO DATE:				
	E OF SYMPTOM ONSET (Must be within 7 days):				
	ASON for NOT prescribing 1st line drug nirmatrelvir/ritonavir (Paxlovid):				
	ABSOLUTE drug interaction contraindication List drug(s):				
	eGFR less than 30 ml/min (Including dialysis patients)				
	ination Status: □ 2-Dose Pfizer or Moderna □ J&J □ Booster/3 ^{rd/} 4 th dose □ Unvaccinated				
	Status: Full Code or No CPR – Support OK No CPR – Allow Natural Death				
6. High Risk Criteria (Please check all that apply):					
	Chronic kidney disease, stages 3 to 5				
	Diabetes				
	Currently receiving immunosuppressant treatment– chemotherapy, immunotherapy, prednisone 20 mg daily or equivalent, OR have chronic immunosuppressive disease				
	Age 65 years or greater				
	Cardiovascular disease or hypertension				
	Chronic lung disease				
	Sickle cell disease				
	Neuro-developmental disorders (ex. Cerebral palsy)				
	Pregnancy: Weeks:				
Date:	Time: Physician Phone Number:				
Physiciar	n Signature:				
Physiciar	Physician Name (Print):				
	· ·				



Page Memorial Hospital

Monoclonal Antibodies for COVID 19

|--|

LERGIES		
eight in Kilogram		Height
DIAGNOSIS: COV		STATUS: OUTPATIENT
		ody medication/route based on availability or variants over 30 seconds using a syringe extension set
Obtain vital signs	prior to the injection/in	fusion and at the end of the injection/infusion
of the fol	lowing occur: Fever, chil	s of an anaphylactic reaction . Stop the injection/infusion if an Ils, nausea, headache, bronchospasm, hypotension, h including urticaria, pruritus, myalgia, or dizziness
Monitor	the patient for one hour	r after the end of the injection/infusion
For allergic/anaph	ylactic reactions	
 Stop the injectio 	n/infusion and notify the	MERT team
• •		e as needed for anaphylaxis (see above anaphylactic reaction signs
 Diphenhydramir 	ne (Benadryl) 25 mg IV o	or PO X 1 dose for itching, swelling, or rash
 Famotidine (Per 	ocid) 40 mg IV x 1 dose f	for itching, swelling, or rash
Methylprednisol	one (Solu-Medrol) 125 m	ng IV x 1 dose for itching, swelling, or rash
 Albuterol sulfate 	(Proventil) 2 puffs inhale	ed every 10 minutes up to 3 doses for wheezing, bronchospa
If a reaction occ	urs, document in EPIC, o	complete risk report, and notify pharmacy
7. 🗆 Copy of Insu	rance Card (front and I	back) attached in case prior authorization required
Provider to Compl	ete:	
8. □ Risks and be	nefits discussed with pat	tient and obtain informed consent
9. □ Patient Inform	nation Sheet provided to	patient/caregiver
Date:	Time:	Physician Phone Number: